CompletedPhase 2NCT00764634
Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B
Studying Botulism
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- DynPort Vaccine Company LLC, A GDIT Company
- Principal Investigator
- William SwiderskiDynPort Vaccine Company LLC
- Intervention
- Placebo (USP sterile saline for injection)(biological)
- Enrollment
- 440 enrolled
- Eligibility
- 18-55 years · All sexes
- Timeline
- 2008 – 2010
Study locations (6)
- Miami Research Associates, Miami, Florida, United States
- University Clinical Research, Inc, Pembroke Pines, Florida, United States
- Johnson County Clin-Trials, Lenexa, Kansas, United States
- Center for Pharmaceutical Research, Kansas City, Missouri, United States
- Wake Research Associates, Raleigh, North Carolina, United States
- Clinical Research Associates of Tidewater, Norfolk, Virginia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00764634 on ClinicalTrials.govOther trials for Botulism
Additional recruiting or active studies for the same condition.